Molecular Pathways Mediating Metastases to the Brain via Epithelial-to-Mesenchymal Transition: Genes, Proteins, and Functional Analysis
- PMID: 26851006
Molecular Pathways Mediating Metastases to the Brain via Epithelial-to-Mesenchymal Transition: Genes, Proteins, and Functional Analysis
Abstract
Background: Brain metastases are the leading cause of morbidity and mortality among patients with disseminated cancer. The development of metastatic disease involves an orderly sequence of steps enabling tumor cells to migrate from the primary tumor and colonize at secondary locations. In order to achieve this complex metastatic potential, a cancer cell is believed to undergo a cellular reprogramming process involving the development of a degree of stemness, via a proposed process termed epithelial-to-mesenchymal transition (EMT). Upon reaching its secondary site, these reprogrammed cancer stem cells submit to a reversal process designated mesenchymal-to-epithelial transition (MET), enabling establishment of metastases. Here, we examined the expression of markers of EMT, MET, and stem cells in metastatic brain tumor samples.
Materials and methods: Immunohistochemical analyses were performed to establish the markers of EMT and MET. Co-expression of these markers was determined by immunofluorescence analysis. Gene-expression analysis was conducted using tissues from brain metastases of primary adenocarcinoma of the lung compared to non-metastatic tissue. Cell proliferation was carried out using 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide S-phase entry analysis, by determining the 5-ethynyl-2'-deoxyuridine incorporation. Scratch wound and chemotactic migration assays were performed in an astrocytic setting.
Results: Metastatic brain tumor samples displayed expression of epithelial markers (zinc finger protein SNAI1 and Twist-related protein-1), as well as the mesenchymal marker vimentin. The stem cell marker CD44 was also highly expressed. Moreover, co-expression of the epithelial marker E-cadherin with the mesenchymal marker vimentin was evident, suggesting a state of transition. Expression analysis of transcription factor genes in metastatic brain tumor samples demonstrated an alteration in genes associated with neurogenesis, differentiation, and reprogramming. Furthermore, tumor cells grown in astrocytic medium displayed increased cell proliferation and enhanced S-phase cell-cycle entry. Additionally, chemotactic signaling from the astrocytic environment promoted tumor cell migration. Primary tumor cells and astrocytes were also shown to grow amicably together, forming cell-to-cell interactions.
Conclusion: These findings suggest that cellular reprogramming via EMT/MET plays a critical step in the formation of brain metastases, where the cerebral milieu provides a microenvironment suitable for the development of metastatic disease.
Keywords: Metastatic tumors; brain metastasis; epithelial-to-mesenchymal transition; homing; invasion; stem cells.
Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
Similar articles
-
Involvement of mTOR signaling pathways in regulating growth and dissemination of metastatic brain tumors via EMT.Anticancer Res. 2015 Feb;35(2):689-96. Anticancer Res. 2015. PMID: 25667447
-
Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases.J Dermatol Sci. 2013 Nov;72(2):93-102. doi: 10.1016/j.jdermsci.2013.07.001. Epub 2013 Jul 15. J Dermatol Sci. 2013. PMID: 23928229
-
Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.Breast Cancer Res Treat. 2014 Nov;148(2):269-77. doi: 10.1007/s10549-014-3159-4. Epub 2014 Oct 8. Breast Cancer Res Treat. 2014. PMID: 25292421
-
Epithelial Mesenchymal Transition in Aggressive Lung Cancers.Adv Exp Med Biol. 2016;890:37-56. doi: 10.1007/978-3-319-24932-2_3. Adv Exp Med Biol. 2016. PMID: 26703798 Review.
-
Mesenchymal-Epithelial Transition and Circulating Tumor Cells in Small Cell Lung Cancer.Adv Exp Med Biol. 2017;994:229-245. doi: 10.1007/978-3-319-55947-6_12. Adv Exp Med Biol. 2017. PMID: 28560677 Review.
Cited by
-
New insights of miRNA molecular mechanisms in breast cancer brain metastasis and therapeutic targets.Noncoding RNA Res. 2023 Sep 28;8(4):645-660. doi: 10.1016/j.ncrna.2023.09.003. eCollection 2023 Dec. Noncoding RNA Res. 2023. PMID: 37818447 Free PMC article.
-
Nanotechnology in brain cancer treatment: The role of gold nanoparticles as therapeutic enhancers.Ibrain. 2025 May 10;11(2):119-145. doi: 10.1002/ibra.12198. eCollection 2025 Summer. Ibrain. 2025. PMID: 40546878 Free PMC article. Review.
-
The Journey of Cancer Cells to the Brain: Challenges and Opportunities.Int J Mol Sci. 2023 Feb 14;24(4):3854. doi: 10.3390/ijms24043854. Int J Mol Sci. 2023. PMID: 36835266 Free PMC article. Review.
-
Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis.Front Oncol. 2018 May 11;8:159. doi: 10.3389/fonc.2018.00159. eCollection 2018. Front Oncol. 2018. PMID: 29868480 Free PMC article. Review.
-
E-cadherin expression in the tumor microenvironment of advanced epidermal growth factor receptor-mutant lung adenocarcinoma and the association with prognosis.BMC Cancer. 2023 Jun 20;23(1):569. doi: 10.1186/s12885-023-10980-6. BMC Cancer. 2023. PMID: 37340370 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous